The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
Abstract
During the past decade, the price of cancer drugs and the spending for cancer treatments by Medicare have increased dramatically. The author outlines the usual tools Medicare uses to control its spending on drugs and discusses the policies that make cancer drugs a special case and prohibit the regulation of their prices and utilization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
Motzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Rixe, O., Oudard, S., Negrier, S., Szczylik, C., Kim, S. T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065044 · Cited by 5,775
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Chemotherapy and the war on cancer
Chabner, B. A., & Roberts, T. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1529 · Cited by 2,154
The Price Tag on Progress — Chemotherapy for Colorectal Cancer
Schrag, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048143 · Cited by 436
Cost of Cancer Care: Issues and Implications
Meropol, N. J., & Schulman, K. A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6081 · Cited by 351
Economics of New Oncology Drug Development
DiMasi, J. A., & Grabowski, H. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0803 · Cited by 348
Lohr, K. N., Brook, R. H., KAMBERG, C. J., Goldberg, G. A., Leibowitz, A. A., KEESEY, J. W., Reboussin, D. M., & Newhouse, J. P. (1986) · PubMed · Cited by 346
Medical Oncologists' Views on Communicating With Patients About Chemotherapy Costs: A Pilot Survey
Schrag, D., & Hanger, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2437 · Cited by 194
Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors
Schneeweiss, S., Walker, A. M., Glynn, R. J., Maclure, M., Dormuth, C., & Soumerai, S. B. (2002) · New England Journal of Medicine · doi:10.1056/nejmsa003087 · Cited by 178
Cited by
Projections of the cost of cancer care in the United States: 2010–2020
Mariotto, A. B., Robin Yabroff, K., Shao, Y., Feuer, E. J., & Brown, M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq495 · Cited by 2,657
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M., Freundlich, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4614 · Cited by 1,059
Carrera, P. M., Kantarjian, H. M., & Blinder, V. S. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21443 · Cited by 876
Medical Care Costs Associated with Cancer Survivorship in the United States
Mariotto, A. B., Enewold, L., Zhao, J., Zeruto, C. A., & Yabroff, K. R. (2020) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-1534 · Cited by 634
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4789 · Cited by 628
Financial Toxicity of Cancer Care: It’s Time to Intervene
Yousuf Zafar, S. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv370 · Cited by 536
Economic Burden of Cancer in the United States: Estimates, Projections, and Future Research
Yabroff, K. R., Lund, J., Kepka, D., & Mariotto, A. (2011) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-11-0650 · Cited by 503
Pricing in the Market for Anticancer Drugs
Howard, D. H., Bach, P. B., Berndt, E. R., & Conti, R. M. (2015) · Journal of Economic Perspectives · doi:10.1257/jep.29.1.139 · Cited by 444
Self-citationThe high price of anticancer drugs: origins, implications, barriers, solutions
Prasad, V., De Jesús, K., & Mailankody, S. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.31 · Cited by 442
Bending the Cost Curve in Cancer Care
Smith, T. J., & Hillner, B. E. (2011) · New England Journal of Medicine · doi:10.1056/nejmsb1013826 · Cited by 391
Fojo, T., Mailankody, S., & Lo, A. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 303
Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs
Mailankody, S., & Prasad, V. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0373 · Cited by 300
Cancer Drugs in the United States: Justum Pretium—The Just Price
Kantarjian, H. M., Fojo, T., Mathisen, M., & Zwelling, L. A. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1845 · Cited by 284
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Hartung, D. M., Bourdette, D. N., Ahmed, S. M., & Whitham, R. H. (2015) · Neurology · doi:10.1212/wnl.0000000000001608 · Cited by 261
Saini, V., Garcia-Armesto, S., Klemperer, D., Paris, V., Elshaug, A. G., Brownlee, S., Ioannidis, J. P. A., & Fisher, E. S. (2017) · The Lancet · doi:10.1016/s0140-6736(16)30947-3 · Cited by 258
The High Cost of Cancer Drugs and What We Can Do About It
Siddiqui, M., & Rajkumar, S. V. (2012) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2012.07.007 · Cited by 255
Basch, E., Loblaw, D. A., Oliver, T. K., Carducci, M., Chen, R. C., Frame, J. N., Garrels, K., Hotte, S., Kattan, M. W., Raghavan, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8404 · Cited by 223
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
Mateo, J., Ong, M., Tan, D. S. P., Gonzalez, M. A., & de Bono, J. S. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.177 · Cited by 96
Kamal, K. M., Covvey, J. R., Dashputre, A., Ghosh, S., Shah, S., Bhosle, M., & Zacker, C. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.2.136 · Cited by 82
Costa, S., Bentley, C., Regier, D. A., McTaggart-Cowan, H., Mitton, C., Burgess, M. M., & Peacock, S. J. (2019) · BMC Public Health · doi:10.1186/s12889-019-7303-2 · Cited by 22
Wäscher, S., Schildmann, J., & Vollmann, J. (2016) · Der Onkologe · doi:10.1007/s00761-016-0119-0 · Cited by 1
Metadata
- Authors
- Bach, P. B.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-02-05
- Volume
- 360
- Issue
- 6
- Pages
- 626-633
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2132047269
- Cited by
- 390
- References
- 20
- FWCI
- 69.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.